Inhibikase Therapeutics Inc. (IKT), a clinical-stage pharmaceutical company, has a clinical trial catalyst to watch in the coming weeks related to its 201 Trial.
The 201 Trial is a phase II study evaluating the company's drug candidate Risvodetinib (also known as IkT-148009) in untreated Parkinson's disease. A total of 126 patients have been randomized in the trial, 120 of which have completed the 12-week double-blind dosing period. Topline data from this study is due this quarter.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com